The "Kick" Revisited in the "Kick and Kill" Strategy
“踢杀”策略中的“踢”重温
基本信息
- 批准号:9016996
- 负责人:
- 金额:$ 22.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-20 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntigensApoptoticBiological AssayCCR5 geneCD4 Positive T LymphocytesCXCR4 geneCell DeathCell SurvivalCell modelCellsCessation of lifeClinicalClinical TrialsDNADetectionEventExhibitsGoalsHIVHIV InfectionsHIV-1IndividualKnowledgeLeadLongevityMemoryPathway interactionsPatientsPlasmaProteinsRNARNA-Directed DNA PolymeraseReaction TimeRestSignal PathwaySourceT-Cell ActivationT-Cell ProliferationT-Lymphocyte SubsetsTestingTherapeuticViralViral Cytopathogenic EffectViral ProteinsViremiaVirusantiretroviral therapycytokineinhibitor/antagonistinsightkillingsmacrophagememory CD4 T lymphocytenon-nucleoside reverse transcriptase inhibitorsnovelpol Gene Productspreventpublic health relevanceresidencesmall molecule
项目摘要
DESCRIPTION (provided by applicant): Although combination antiretroviral therapy (cART) can reduce plasma HIV RNA levels in most infected individuals to below the detection limit of clinical assays, it is not curative and persistent viremia is detected in the majority of patients.A rare, but extremely stable, HIV proviral DNA reservoir in resting CD4+ T cells (i.e. the latent reservoir) is thought to be the major source of persistent viremia. This latent reservoir can produce infectious virus when the host cell is reactivated by recall antigen (or by various cytokines), that can reseed HIV infection if cART is discontinued. Eradication of the latent reservoir may lead to a cure for HIV infection. Currently, a "kick and kill" strategy is being testd in ongoing clinical trials as a pharmacological approach to deplete the latent HIV reservoir. This strategy involves the administration of a latency reversing agent (LRA) which induces HIV out of latency (the "kick"), that in turn facilitates death of the infected cells by viral cytopathic effets (the "kill"). Several distinct therapeutic classes of LRAs have been identified that effectively "kick" HIV out of latency. In contrast, our understanding of the "kill" in HIV-infected resting CD4 T cells is extremely limited. The primary goal of this study is to comprehensively assess the "kill in the "kick and kill" strategy, using novel primary cell models of latency in highly purified naïe (TN) and central memory (TCM) CD4+ T cells. Collectively, we anticipate that these studies will yield important insights into HIV persistence, and may have the potential to identify new targets or approaches to eradicate latent HIV infection. Furthermore, they could help explain clinical finding from ongoing trials that are focused on depleting the latent HIV reservoir.
描述(通过应用提供):尽管抗逆转录病毒疗法(CART)可以将大多数感染个体的血浆HIV RNA水平降低到低于临床评估的检测限制,但在大多数患者中却没有治愈,并且在大多数患者中检测到持续性病毒性。持续的病毒血症。当宿主细胞被召回抗原(或各种细胞因子)重新激活时,该潜在储层会产生传染性病毒,如果停用了CART,则可以恢复HIV感染。消除潜在储层可能会导致治愈HIV感染。目前,正在进行的临床试验中,正在对“踢和杀戮”策略进行测试,以此作为耗尽潜在艾滋病毒水库的药物方法。该策略涉及延迟逆转剂(LRA)的给药,该潜伏期逆转剂(LRA)从潜伏期中诱导艾滋病毒(“踢”),进而促进了受病毒细胞病毒效应(“杀死”)的感染细胞死亡。已经确定了几种不同的LRA治疗类别,它们从潜伏期中有效地“踢”了HIV。相反,我们对HIV感染的静止CD4 T细胞中“杀死”的理解非常有限。这项研究的主要目标是全面评估“踢和杀死”策略中的“杀死”,使用高度纯化的幼稚(TN)和中央记忆(TCM)CD4+ T细胞中的新型主要细胞模型,我们共同预计,这些研究将产生对HIV持续性的重要见解,并可能通过启用HIV的启发性地进行启发,从而识别出新的目标,从而降低了辐射效率。旨在耗尽潜在艾滋病毒水库的试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NICOLAS PAUL SLUIS-CREMER其他文献
NICOLAS PAUL SLUIS-CREMER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NICOLAS PAUL SLUIS-CREMER', 18)}}的其他基金
Elucidating the role of B cell mediated trans infection in the establishment of the latent HIV-1 reservoir
阐明 B 细胞介导的反式感染在潜伏 HIV-1 病毒库建立中的作用
- 批准号:
10675438 - 财政年份:2022
- 资助金额:
$ 22.34万 - 项目类别:
Elucidating the role of B cell mediated trans infection in the establishment of the latent HIV-1 reservoir
阐明 B 细胞介导的反式感染在潜伏 HIV-1 病毒库建立中的作用
- 批准号:
10402053 - 财政年份:2022
- 资助金额:
$ 22.34万 - 项目类别:
Potent inhibition of HIV-1 latency reversal by PF 03758309
PF 03758309 有效抑制 HIV-1 潜伏期逆转
- 批准号:
10409846 - 财政年份:2021
- 资助金额:
$ 22.34万 - 项目类别:
Potent inhibition of HIV-1 latency reversal by PF 03758309
PF 03758309 有效抑制 HIV-1 潜伏期逆转
- 批准号:
10326435 - 财政年份:2021
- 资助金额:
$ 22.34万 - 项目类别:
The "Kick" Revisited in the "Kick and Kill" Strategy
“踢杀”策略中的“踢”重温
- 批准号:
9301475 - 财政年份:2016
- 资助金额:
$ 22.34万 - 项目类别:
相似国自然基金
基于溶酶体依赖性凋亡及抗原呈递功能的GL-V9抗AML作用的研究
- 批准号:82173847
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
Spag6基因缺陷致小鼠前庭功能异常的机制研究
- 批准号:81900940
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
Tn抗原通过DR4/DR5调控结直肠癌细胞对TRAIL敏感性的机制研究
- 批准号:81902800
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
超抗原SEB在慢性鼻-鼻窦炎的发病过程中对鼻黏膜上皮屏障功能的影响与机制研究
- 批准号:81900915
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
转录因子BORIS转位线粒体调控结直肠癌发生发展的机制研究
- 批准号:31871393
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:面上项目
相似海外基金
Flt3l gene-modified cDC1 in situ vaccination in NSCLC: mechanisms and therapeutic application
Flt3l 基因修饰的 cDC1 原位疫苗接种在 NSCLC 中的作用:机制和治疗应用
- 批准号:
10585591 - 财政年份:2023
- 资助金额:
$ 22.34万 - 项目类别:
Engineered Nanoformulation for Immune-modulation in Cancer
用于癌症免疫调节的工程纳米制剂
- 批准号:
10719487 - 财政年份:2023
- 资助金额:
$ 22.34万 - 项目类别:
Source and homeostatic functions of anti-adduct IgM in humans
人类抗加合物 IgM 的来源和稳态功能
- 批准号:
10680950 - 财政年份:2023
- 资助金额:
$ 22.34万 - 项目类别:
Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming
通过多因子 mRNA 介导的 T 细胞重编程增强黑色素瘤 TIL 功效
- 批准号:
10721549 - 财政年份:2023
- 资助金额:
$ 22.34万 - 项目类别:
Modeling Dynamic Immune Cell Modulation in a 3-D Tissue Engineered Platform to Enhance Patient-specific Immunotherapy for Lung Cancer
在 3D 组织工程平台中模拟动态免疫细胞调节,以增强肺癌患者特异性免疫治疗
- 批准号:
10518637 - 财政年份:2022
- 资助金额:
$ 22.34万 - 项目类别: